24小时热门版块排行榜

返回列表

当前主题已经存档。

abcd888898

银虫 (正式写手)

应助: 0 (幼儿园)
金币: 646.8
散金: 11
帖子: 326
在线: 39.4小时
虫号: 417550
注册: 2007-07-01
性别: GG
专业: 药品注册

[交流] 【转帖】Novo Nordisk starts phase 1 trial with long-acting oral GLP-1 analogue

Emisphere earns 2 million US dollar milestone payment(13 Jan 2010) Novo Nordisk today announced that it has initiated its first phase 1 clinical trial with a long-acting oral GLP-1 analogue (NN9924). This milestone releases a 2 million dollar payment to Emisphere Technologies, Inc., whose proprietary Eligen® Technology is used in the formulation of NN9924.
GLP-1 (Glucagon-Like Peptide-1) is a natural hormone involved in controlling blood sugar levels. It stimulates the release of insulin only when blood sugar levels become too high. In people with type 2 diabetes, GLP-1 secretion is often impaired.
The aim of the trial, which is conducted in the UK, is to investigate the safety, tolerability and bioavailability of NN9924 in healthy volunteers. Results from the trial, which is planned to enrol about 155 people, are expected to be reported in 2011.
There are many challenges in developing a formulation of GLP-1 for oral use, in particular obtaining adequate bioavailability (absorption of the drug in the body). NN9924 addresses some of the key challenges, and utilises the Eligen® formulation technology from Emisphere to facilitate GLP-1 absorption from the gut.

回复此楼

» 猜你喜欢

1楼 2010-01-14 20:54:59

已阅回复此楼关注TA 给TA发消息送TA红花 TA的回帖

相关版块跳转我要订阅楼主 abcd888898 的主题更新

返回列表